

SUSIE SHI

Beijing

+86 10 5769 4275

susie.shi@fangdalaw.com

PRACTICE AREA

SUSIE SPECIALIZES IN MERGERS AND ACQUISITIONS, PRIVATE EQUITY INVESTMENTS, JOINT VENTURES, OUTBOUND INVESTMENTS, FOREIGN DIRECT INVESTMENTS AND GENERAL CORPORATE MATTERS.

Education

- Juris Doctor, University of Sydney, Australia
- Bachelor of Laws, Southwest University of Political Science & Law, China

Professional Qualification

- Admitted to practice in California
- Admitted to practice in New South Wales (Australia)
- Admitted to practice in the PRC

Work Language

- Mandarin
- English
- Japanese

Professional Background

- Before joining the firm, Ms. Shi worked at Ashurst Australia and IBM Australia.

REPRESENTATIVE MATTERS AND CASES

- Represented Pirelli S.p.A. in connection with its integration with ChemChina's subsidiaries, its various investments in China, and general corporate matters in China
- Represented DiaSys Diagnostic System GmbH, a German based multinational company which specializes in the development and manufacturing of diagnostic system solutions, and certain other minority shareholders in the sale of their minority equity interest in two Chinese JVs to Leadman, an A-share listed company
- Represented Innovate Corp., a NYSE listed investment company, in the sale of its minority equity interest in HMN International Co, Limited to various entities under Hengtong Group Co., Ltd., an A-share listed company focused on the telecommunication sector
- Represented China Jianyin Investment Ltd., a state-owned Chinese investment company, in its sale of it its controlling interest in SGD Pharma, a leading global manufacturer of primary glass packaging for the pharmaceutical industry headquartered in France, to a European private equity firm PAI Partners
- Represented MSU S.A., one of the largest agricultural companies in Argentina, in its 100% acquisition of Oro Esperanza Agro S.A (controlled by Chongqing Grain Group Co.,Ltd.) through tender procedures with Chongqing United Assets and Equity Exchange
- Represented Manbang Group, the largest truck matching platform in China, in its strategic investment in Truckpad Tecnologia e Logística S.A., one of the leading truck platforms in the Latin America region
- Represented two potential private equity firms as a consortium in participating in the auction sale of the China assets of Mundipharma International Ltd., a global pharmaceutical company owned by the Sackler family
- Represented Nexelis Laboratories, a Canadian CRO company, in its proposed strategic collaboration with JOINN Laboratories
- Represented Mylan N.V., as its PRC counsel, in its combination with Upjohn, the off-patent branded and generic established medicines business of Pfizer Inc. so as to create a new global pharmaceutical company
- Represented a global pharmaceutical company in its proposed strategic alliance with a leading pharmaceutical group in China
- Represented IntelliCentrics Global Holdings Ltd., one of the North America's largest and most trusted provider of healthcare vendor credentialing services, in its formation of an equity joint venture with James Li in China

- Represented IntelliCentrics Global Holdings Ltd. in its global offering and listing on the Main Board of the Stock Exchange of Hong Kong Limited as its PRC legal counsel
- Represented XJ Capital in its proposed acquisition of a global medical equipment manufacturer.
- Represented a major PRC state-owned company in its proposed acquisition of a European medical device company
- Represented a leading private equity fund in its proposed acquisition of certain businesses from a computer software technology corporation
- Represented CITIC PE as the lead investor in its equity investment in the precision medicine business of 3D Medicines (3DMed), one of the first companies to provide oncology precision medical testing services in China
- Represented Hillhouse Capital as the lead investor in its equity investment in the Series B financing of Hemo Bioengineering, a Singapore-based medical device company with a focus on treating stroke patients.
- Represented Huaxing Growth Capital as one of the co-lead investors in its participation in the series A round of financing in Shandong Weigao Interventional Medical Technology Co., Ltd. As a subsidiary of the Weigao Group, Weigao Jieru is committed to the R&D, production and sales of interventional medical devices in the field of vascular, neuro and peripheral.
- Represented Shunwei Capital in its investment in the series A financing of Healife Group, one of China's leading professional conference organizer specialized in medical academic conferences and healthcare events
- Represented Alibaba in its formation of an equity joint venture with Accenture where Alibaba and Accenture will join forces in the business of SaaS with special focus on consumer goods new retail, commuting and digital energy
- Represented Didi Chuxing in its acquisition of Uber China
- Represented a Chinese state-owned enterprise in its proposed sale of two factories in Australia
- Represented a Chinese company in its proposed sale of its shares in a German listed company to one of the world's leading automobile manufacturers
- Represented a leading German thin film photovoltaic company in its proposed joint venture with a major PRC state-owned company
- Represented various foreign companies in forming joint ventures in China with their Chinese partners
- Represented China International Capital Corporation in the Series D financing of WorkTrans led by Tencent
- Represented Alibaba in its RMB 3 billion strategic investment in Shenzhou Zhuanche
- Represented RC Semi-Holdings, an investment platform under CITIC Capital, in its investments in various companies engaged in semiconductor industry
- Represented CITIC Capital (as the lead investor) in its investment in the series A financing of Feipeng (Aerospace Times Feipeng Co., Ltd.), involving an aggregate transaction price of RMB 300 million
- Represented various venture capital and private equity funds in their equity investments and sales, including but not limited to Warburg Pincus, Yunfeng Capital, CPE, China Media Capital, Shunwei Capital, XJ Capital, CITIC Capital, Trustbridge Partners, China Growth Capital, and IDG Capital